Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026 
South Korean Won Slides Despite Government Efforts to Stabilize Currency Markets 
U.S. Dollar Steadies Ahead of Fed Minutes as Markets Eye Policy Divisions 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
South Korea Factory Output Misses Forecasts in November Amid Ongoing Economic Uncertainty 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading 
Oil Prices Slide in 2025 as Oversupply and Geopolitical Risks Shape Market Outlook 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Federal Reserve Begins Treasury Bill Purchases to Stabilize Reserves and Money Markets 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
U.S. Stock Index Futures Steady as Markets Await Fed Policy Clues in Holiday-Thinned Trade 
Asian Markets End Year on AI Optimism as Precious Metals and Currencies Shine 
Samsung Biologics is said to be most likely to sign a deal with Moderna, an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. The contract is for the production of COVID-19 vaccine in South Korea.
Samsung and Moderna’s anticipated announcement
As per The Korea Herald, Samsung Biologics and Moderna may work together to boost vaccine production amid the vaccine shortage in the country. It was reported that the two companies may formally announce their deal at the summit where S. Korea’s President Moon Jae In and US President Joe Biden are set to meet.
A local TV station was said to have reported about the possibility of this business negotiation last weekend. Other media outlets followed suit and shared related reports.
In any case, Samsung Biologics did not confirm if it will indeed sign a contract with Moderna for vaccine production and supply. It was quite vague as the Incheon-based biotechnology company did not deny the reports as well. In a regulatory filing, there was a statement saying there is no decision yet about Moderna’s COVID-19 being manufactured in S. Korea.
The guessing game
There have been lots of reports as to which company that Moderna will partner with as it is reported to be very interested in producing its vaccine in the said Asian region. Various firms were mentioned, and initial rumor is that it will work with Hanmi Pharmaceuticals or GC Pharma.
And now, the most promising candidate for a deal with Moderna is reportedly Samsung Biologics that was suddenly added to the list of potential partners. Moderna’s CEO, Stephane Bancel, may visit S. Korea this month to survey as per the reports.
Maeil Business News pointed out that it was also reported earlier that Samsung Biologics will produce Pfizer vaccine but this was vehemently denied but with Moderna, it was different as the Korean firm would not acknowledge or deny and only saying that “nothing has been finalized yet.”
Thus, it was speculated that Samsung Biologics and Moderna are more likely to confirm their contract soon. The rumors of the partnership were heightened by the fact that the American pharma already started looking for senior executives for its office that will soon open in Korea.
